Hoersholm, 2013-09-03 18:06 CEST (GLOBE NEWSWIRE) --
Company announcement no.22/2013
Chr. Hansen announces its long-term strategy. The strategy targets organic revenue growth of 7-10% per annum in the coming five years, combined with further improvements in EBIT margin before special items. The improvement in margin is expected to be lower than historically due to investments in innovation, emerging markets, and the exploration of new growth opportunities in animal health, plant protection, and second-generation human health solutions.
For further information, please contact:
Cees de Jong, CEO Tel: +45 4574 7474
Anders Mohr Christensen, Senior Director IR Tel: +45 4574 7618
Forward-looking statements
The forward-looking statements in this announcement are subject to risks and uncertainties, as various factors, many of which are beyond the control of Chr. Hansen Holding A/S, may cause actual developments and results to differ materially from the expectations expressed in the announcement.
About Chr. Hansen
Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical, and agricultural industries. Products center around cultures, enzymes, probiotics, and natural colors, and all solutions are based on strong research and development competencies coupled with significant technology investments. Revenue in the 2011/12 financial year was EUR 699 million. The company holds a leading market position in all its divisions: Cultures & Enzymes, Health & Nutrition, and Natural Colors. It has more than 2,450 dedicated employees in over 30 countries. Chr. Hansen was founded in 1874 and is listed on NASDAQ OMX Copenhagen. For further information, please visit www.chr-hansen.com.
